Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy
Abstract
:1. Introduction
2. Materials and Methods
2.1. Biochemical Assays
AOPPs Analysis
2.2. Statistical Analysis
3. Results
3.1. DM Group
3.2. HT Group
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Kramer, A.; Pippias, M.; Stel, V.S.; Bonthuis, M.; Diez, J.M.A.; Afentakis, N.; De La Torre, R.A.; Ambühl, P.; Bikbov, B.; Caamaño, E.B.; et al. Renal replacement therapy in Europe: A summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. Clin. Kidney J. 2016, 9, 457–469. [Google Scholar] [CrossRef] [PubMed]
- Brownlee, M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005, 54, 1615–1625. [Google Scholar] [CrossRef] [PubMed]
- Forbes, J.M.; Coughlan, M.T.; Cooper, M.E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57, 1446–1454. [Google Scholar] [CrossRef] [PubMed]
- Mehrotra, S.; Ling, K.L.; Bekele, Y.; Gerbino, E.; Earle, K.A. Lipid hydroperoxide and markers of renal disease susceptibility. in African–Caribbean and Caucasian patients with Type 2 diabetes mellitus. Diabet. Med. 2001, 18, 109–115. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Burden: Mortality, Morbidity and Risk Factors of NCDs. Available online: http://www.who.int/nmh/publications/ncd report_chapter1.pdf. (accessed on 2 February 2015).
- Calabrese, V.; Mancuso, C.; Sapienza, M.; Puleo, E.; Calafato, S.; Cornelius, C.; Finocchiaro, M.; Mangiameli, A.; Di Mauro, M.; Stella, A.M.G.; et al. Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones 2007, 12, 299–306. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Amore, A.; Cirina, P.; Conti, G.; Cerutti, F.; Bagheri, N.; Emancipator, S.N.; Coppo, R. Amadori-configurated albumin induces nitric oxide-dependent apoptosis of endothelial cells: A possible mechanism of diabetic vasculopathy. Nephrol. Dial. Transplant. 2004, 19, 53–60. [Google Scholar] [CrossRef]
- Mennuni, S.; Rubattu, S.; Pierelli, G.; Tocci, G.; Fofi, C.; Volpe, M. Hypertension and kidneys: Unraveling complex molecular mechanisms underlying hypertensive renal damage. J. Hum. Hypertens. 2014, 28, 74–79. [Google Scholar] [CrossRef]
- Sies, H. Oxidative stress: A concept in redox biology and medicine. Redox Biol. 2015, 4, 180–183. [Google Scholar] [CrossRef]
- Sack, M.N.; Fyhrquist, F.Y.; Saijonmaa, O.J.; Fuster, V.; Kovacic, J.C. Basic Biology of Oxidative Stress and the Cardiovascular System: Part 1 of a 3-Part Series. J. Am. Coll. Cardiol. 2017, 70, 196–211. [Google Scholar] [CrossRef]
- Massaro, M.; Scoditti, E.; Carluccio, M.A.; De Caterina, R. Oxidative stress and vascular stiffness in hypertension: A renewed interest for antioxidant therapies? Vasc. Pharmacol. 2019, 116, 45–50. [Google Scholar] [CrossRef]
- Modaresi, A.; Nafar, M.; Sahraei, Z. Oxidative stress in chronic kidney disease. Iran. J. Kidney Dis. 2015, 9, 165–179. [Google Scholar] [PubMed]
- Rehman, K.; Akash, M.S.H. Mechanism of Generation of Oxidative Stress and Pathophysiology of Type 2 Diabetes Mellitus: How Are They Interlinked? J. Cell. Biochem. 2017, 118, 3577–3585. [Google Scholar] [CrossRef]
- Singh, R.; Devi, S.; Gollen, R. Role of free radical in atherosclerosis, diabetes and dyslipidaemia: Larger-than-life. Diabetes Metab. Res. Rev. 2015, 31, 113–126. [Google Scholar] [CrossRef] [PubMed]
- Alvarez, A.; Sanz, M.J. Reactive oxygen species mediate angiotensin II-induced leukocyte–endothelial cell interactions in vivo. J. Leukoc. Biol. 2001, 70, 199–206. [Google Scholar]
- Ricci, J.E.; Gottlieb, R.A.; Green, D.R. Caspase-mediated loss of mitochondrial function and generation of reactive oxygen species during apoptosis. J. Cell. Biol. 2003, 160, 65–75. [Google Scholar] [CrossRef]
- Ortiz, A.; Lorz, C.; Justo, P.; Catalan, M.P.; Egido, J. Contribution of apoptotic cell death to renal injury. J. Cell. Mol. Med. 2001, 5, 18–32. [Google Scholar] [CrossRef] [PubMed]
- Sowers, J.R. Hypertension, angiotensin II, and oxidative stress. N. Engl. J. Med. 2002, 346, 1999–2001. [Google Scholar] [CrossRef]
- Wilcox, C.S. Reactive oxygen species: Roles in blood pressure and kidney function. Curr. Hypertens. Rep. 2002, 4, 160–166. [Google Scholar] [CrossRef]
- Zhao, Y.; Zhang, L.; Ouyang, X.; Jiang, Z.; Xie, Z.; Fan, L.; Zhu, D.; Li, L. Advanced oxidation protein products play critical roles in liver diseases. Eur. J. Clin. Invest. 2019, 5, e13098. [Google Scholar] [CrossRef]
- Piwowar, A. Advanced oxidation protein products. Part I. Mechanism of the formation, characteristics and property. Polski Merkur. Lek. Organ Polskiego Towar. Lek. 2010, 28, 166–169. [Google Scholar]
- Witko-Sarsat, V.; Friedlander, M.; Capeillère-Blandin, C.; Nguyen-Khoa, T.; Nguyen, A.T.; Zingraff, J.; Jungers, P.; Descamps-Latscha, B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996, 49, 1304–1313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kalousova, M.; Skrha, J.; Zima, T. Advanced glycation endproducts and advanced oxidation protein products in patients with diabetes mellitus. Physiol. Res. 2002, 51, 597–604. [Google Scholar] [PubMed]
- Klisic, A.; Isakovic, A.; Kocic, G.; Kavaric, N.; Jovanovic, M.; Zvrko, E.; Skerovic, V.; Ninic, A. Relationship between Oxidative Stress, Inflammation and Dyslipidemia with Fatty Liver Index in Patients with Type 2 Diabetes Mellitus. Exp. Clin. Endocrinol. Diabetes 2018, 126, 371–378. [Google Scholar] [CrossRef] [PubMed]
- Villalpando Sánchez, D.C.; Alvarez Aguilar, C.; Gómez García, A. Advanced oxidation protein products and their relationship with cardiovascular risk factors in young apparently healthy people. Clin. Investig. Arterioscler. 2017, 29, 209–215. [Google Scholar] [CrossRef] [PubMed]
- Feng, W.; Zhang, K.; Liu, Y.; Chen, J.; Cai, Q.; He, W.; Zhang, Y.; Wang, M.H.; Wang, J.; Huang, H. Advanced oxidation protein products aggravate cardiac remodeling via cardiomyocyte apoptosis in chronic kidney disease. Am. J. Physiol. Heart Circ. Physiol. 2018, 314, H475–H483. [Google Scholar] [CrossRef] [PubMed]
- Yıldırım, E.; İpek, E.; Bavunoğlu, I.; Yıldırım, N.; Cengiz, M.; Yavuzer, S.; Yavuzer, H.; Erman, H.; Uzun, H. The impact of protein oxidation on sustained and white coat hypertension. Anatol. J. Cardiol. 2017, 17, 210–216. [Google Scholar] [CrossRef] [PubMed]
- Xu, H.; Cabezas-Rodriguez, I.; Qureshi, A.R.; Heimburger, O.; Barany, P.; Snaedal, S.; Anderstam, B.; Helin, A.C.; Carrero, J.J.; Stenvinkel, P.; et al. Increased Levels of Modified Advanced Oxidation Protein Products Are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients. Perit. Dial. Int. 2015, 35, 460–470. [Google Scholar] [CrossRef]
- Ou, H.; Huang, Z.; Mo, Z.; Xiao, J. The Characteristics and Roles of Advanced Oxidation Protein Products in Atherosclerosis. Cardiovasc. Toxicol. 2017, 17, 1–12. [Google Scholar] [CrossRef]
- Tsukahara, H.; Sekine, K.; Uchiyama, M.; Kawakami, H.; Hata, I.; Todoroki, Y.; Hiraoka, M.; Kaji, M.; Yorifuji, T.; Momoi, T.; et al. Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes. Pediatr. Res. 2003, 54, 419–424. [Google Scholar] [CrossRef]
- Kohner, E.M. The lesions and natural history of diabetic retinopathy. In Textbook of Diabetes; Pickup, J., Williams, G., Eds.; Blackwell Scientific: Oxford, UK, 1991; pp. 575–588. [Google Scholar]
- Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Rogers, N.; Greene, T.; Roth, D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999, 130, 461–470. [Google Scholar] [CrossRef]
- Ramakrishna, V.; Jailkhani, R. Evaluation of oxidative stress in Insulin Dependent Diabetes Mellitus (IDDM) patients. Diagn. Pathol. 2007, 2, 22. [Google Scholar] [CrossRef] [PubMed]
- Piwowar, A.; Knapik-Kordecka, M.; Szczecińska, J.; Warwas, M. Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy. Diabetes Metab. Res. Rev. 2008, 24, 549–553. [Google Scholar] [CrossRef] [PubMed]
- O’Brien, S.F.; Watts, G.F.; Powrie, J.K.; Shaw, K.M.; Miller, N.J. Lipids, lipoproteins, antioxidants and glomerular and tubular dysfunction in type1 diabetes. Diabetes Res. Clin. Pract. 1996, 32, 81–90. [Google Scholar] [CrossRef]
- Paneni, F.; Beckman, J.A.; Creager, M.A.; Cosentino, F. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Eur. Heart J. 2013, 34, 2436–2443. [Google Scholar] [CrossRef] [PubMed]
- Jakuš, V.; Šándorová, E.; Kalninová, J.; Krahulec, B. Monitoring of Glycation, Oxidative Stress and Inflammation in Relation to the Occurrence of Vascular Complications in Patients with Type 2 Diabetes Mellitus. Physiol. Res. 2014, 63, 297–309. [Google Scholar] [PubMed]
- Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414, 813–820. [Google Scholar] [CrossRef] [PubMed]
- Sedeek, M.; Callera, G.; Montezano, A.; Gutsol, A.; Heitz, F.; Szyndralewiez, C.; Page, P.; Kennedy, C.R.J.; Burns, K.D.; Touyz, R.M.; et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: Implications in type 2 diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 2010, 299, F1348–F1358. [Google Scholar] [CrossRef]
- Lacava, V.; Pellicanò, V.; Ferrajolo, C.; Cernaro, V.; Visconti, L.; Conti, G.; Buemi, M.; Santoro, D. Novel avenues for treating diabetic nephropathy: New investigational drugs. Expert Opin. Investig. Drugs 2017, 26, 445–462. [Google Scholar] [CrossRef]
- Liang, X.; Duan, N.; Wang, Y.; Shu, S.; Xiang, X.; Guo, T.; Yang, L.; Zhang, S.; Tang, X.; Zhang, J. Advanced oxidation protein products induce endothelial-to-mesenchymal transition in human renal glomerular endothelial cells through induction of endoplasmic reticulum stress. J. Diabetes Complicat. 2016, 30, 573–579. [Google Scholar] [CrossRef]
- Amore, A.; Formica, M.; Giacchino, F.; Gigliola, G.; Bonello, F.; Conti, G.; Camilla, R.; Coppo, R. N-Acetylcysteine in hemodialysis diabetic patients resets the activation of NF-kB in lymphomonocytes to normal values. J. Nephrol. 2013, 26, 778–786. [Google Scholar] [CrossRef]
- Touyz, R.M. Recent advances in intracellular signaling in hypertension. Curr. Opin. Nephrol. Hypertens. 2003, 12, 165–174. [Google Scholar] [CrossRef] [PubMed]
- Santoro, D.; Bellinghieri, G.; Conti, G.; Pazzano, D.; Satta, E.; Costantino, G.; Savica, V. Endothelial dysfunction in chronic renal failure. J. Ren. Nutr. 2010, 20, S103–S108. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez-Puyol, M.; Griera-Merino, M.; Perez-Rivero, G.; Diez-Marques, M.L.; Ruiz-Torres, M.P.; Rodriguez-Puyol, D. Angiotensin II induces a rapid and transient increase of reactive oxygen species. Antioxid. Redox Signal. 2002, 4, 869–875. [Google Scholar] [CrossRef] [PubMed]
- Tojo, A.; Onozato, M.L.; Kobayashi, N.; Goto, A.; Matsuoka, H.; Fujita, T. Angiotensin II and oxidative stress in Dahl salt-sensitive rat with heart failure. Hypertension 2002, 40, 834–839. [Google Scholar] [CrossRef] [PubMed]
- Lodha, S.; Dani, D.; Mehta, R.; Bhaskaran, M.; Reddy, K.; Ding, G.; Singhal, P.C. Angiotensin II-induced mesangial cell apoptosis: Role of oxidative stress. Mol. Med. 2002, 8, 830–840. [Google Scholar] [CrossRef] [PubMed]
- Shi, X.Y.; Hou, F.F.; Niu, H.X.; Wang, G.B.; Xie, D.; Guo, Z.J.; Zhou, Z.M.; Yang, F.; Tian, J.W.; Zhang, X. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 2008, 149, 1829–1839. [Google Scholar] [CrossRef] [PubMed]
- Garibaldi, S.; Barisione, C.; Marengo, B.; Ameri, P.; Brunelli, C.; Balbi, M.; Ghigliotti, G. Advanced Oxidation Protein Products-Modified Albumin Induces Differentiation of RAW264.7 Macrophages into Dendritic-Like Cells Which Is Modulated by Cell Surface Thiols. Toxins 2017, 9, 27. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Zhang, T.; Geng, J.; Xu, L.; Liu, J.; Tian, J.; Zhou, Z.M.; Nie, J.; Bai, X. Advanced oxidation protein products promote lipotoxicity and tubulointerstitial fibrosis via CD36/β-catenin pathway in diabetic nephropathy. Antioxid. Redox Signal. 2019, 31. [Google Scholar] [CrossRef]
- Rong, G.; Tang, X.; Guo, T.; Duan, N.; Wang, Y.; Yang, L.; Zhang, J.; Liang, X. Advanced oxidation protein products induce apoptosis in podocytes through induction of endoplasmic reticulum stress. J. Physiol. Biochem. 2015, 71, 455–570. [Google Scholar] [CrossRef]
- Pan, H.Z.; Zhang, L.; Guo, M.Y.; Sui, H.; Li, H.; Wu, W.H.; Qu, N.Q.; Liang, M.H.; Chang, D. The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol. 2010, 47, 71–76. [Google Scholar] [CrossRef]
- Liang, M.; Wang, J.; Xie, C.; Yang, Y.; Tian, J.W.; Xue, Y.M.; Hou, F.F. Increased plasma advanced oxidation protein products is an early marker of endothelial dysfunction in type 2 diabetes patients without albuminuria 2. J. Diabetes 2014, 6, 417–426. [Google Scholar] [CrossRef] [PubMed]
Clinical Characteristics | Healthy Control Group (HCG) | Diabetes Mellitus (DM) | Diabetic Nephropathy (DN) | Chronic Renal Failure for DN | Hypertension (HT) | Chronic Renal Failure for HT |
---|---|---|---|---|---|---|
n | 30 | 24 | 18 | 20 | 26 | 30 |
Age (years) | 53.83 ± 12.65 | 51.85 ± 13.46 | 52.65 ± 12.28 | 54.12 ± 11.75 | 53.28 ± 13.72 | 52.91 ± 11.45 |
Sex (M/F) | 13/17 | 10/14 | 8/10 | 9/11 | 11/15 | 14/16 |
Serum Glucose (mmol/l) | 4.76 ± 0.39 | 10.38 ± 2.41 a | 11.55 ± 2.85 a | 11.03 ± 3.08 a | 4.58 ± 0.28 | 4.97 ± 0.45 |
Insulin (mmol/l) | - | 11.39 ± 8.75 | 10.66 ± 6.09 | 11.69 ± 7.61 | - | - |
Systolic Blood Pressure (mmHg) | 130.2 ± 6.58 | 132.45 ± 8.45 | 133.48 ± 9.5 | 137.5 ± 10.6 a | 148.85 ± 8.3 a | 149.5 ± 7.6 a |
Diastolic Blood Pressure (mmHg) | 75.68 ± 8.8 | 77.42 ± 6.8 | 78.21 ± 7.25 | 84.3 ± 5.65 a | 80.85 ± 7.55 | 85.451 ± 8.05 |
Variables Considered in HCG and Diabetic Patients | Healthy Control Group (HCG) | Diabetes Mellitus (DM) | Diabetic Nephropathy (DN) | Chronic Renal Failure for DN |
---|---|---|---|---|
n | 30 | 24 | 18 | 20 |
Plasma levels of AOPP (micromole/l) | 124 ± 47 | 155 ± 110 | 252 ± 163 a | 225 ± 95 a |
Duration of the disease (months) | - | 31.05 ± 32.15 | 69.83 ± 41.18 b | 75.43 ± 52.85 b |
Serum creatinine (micromole/l) | 58.85 ± 12.82 | 63.73 ± 11.06 | 65.11 ± 12.23 | 77.35 ± 21.08 c |
Urinary albumin excretion rate (microgram/min) | <20 | <20 | >200 | >200 |
Variables Considered in HCG and Hypertension Patients | Healthy Group Control (HCG) | HT | Chronic Renal Failure for HT |
---|---|---|---|
n | 30 | 26 | 30 |
Plasma levels of AOPP (micromole/l) | 124 ± 47 | 175 ± 97 a | 217 ± 110 b |
Duration of the disease (months) | - | 33.89 ± 31.75 | 70.03 ± 48.58 c |
Serum creatinine (micromole/l) | 58.85 ± 12.82 | 64.22 ± 14.53 | 74.7 ± 18.81 d |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Conti, G.; Caccamo, D.; Siligato, R.; Gembillo, G.; Satta, E.; Pazzano, D.; Carucci, N.; Carella, A.; Del Campo, G.; Salvo, A.; et al. Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy. Medicina 2019, 55, 675. https://doi.org/10.3390/medicina55100675
Conti G, Caccamo D, Siligato R, Gembillo G, Satta E, Pazzano D, Carucci N, Carella A, Del Campo G, Salvo A, et al. Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy. Medicina. 2019; 55(10):675. https://doi.org/10.3390/medicina55100675
Chicago/Turabian StyleConti, Giovanni, Daniela Caccamo, Rossella Siligato, Guido Gembillo, Ersilia Satta, Dario Pazzano, Nicolina Carucci, Antonio Carella, Giuliana Del Campo, Antonino Salvo, and et al. 2019. "Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy" Medicina 55, no. 10: 675. https://doi.org/10.3390/medicina55100675